Omega-3 Fatty Acid Deficiency Replacement in Early Schizophrenia

Inclusion Criteria: * Between the ages of 8-25 years. * Diagnosis of MDD and not exhibited symptom remission CDRS-R (\> 28 but \< 40) despite being administered a standard therapeutic dose of an SSRI continuously for a minimum of 6 weeks. * Ability and willingness to provide assent and informed, written consent from at least one biological parent. * Present with biological parent or legal guardian. * Willingness to maintain current dietary habits. * Permission from treating physician * Able to perform fMRI/MRS. Exclusion Criteria: * Inability or unwillingness to provide consent. * Antecedent or concurrent serious medical illness. * Clinically unstable medical disease, including cardiovascular, hepatic insufficiency, severe renal impairment, gastrointestinal, pulmonary, metabolic, endocrine, obesity or other systemic disease. * History of seizures, excluding febrile seizures in childhood. * Patients requiring treatment with any drug which might obscure the action of the study treatment. * Female patients who are either pregnant or lactating. * Clinically significant laboratory abnormalities in the last year on CBC or TSH tests. * Judged clinically to be at suicidal risk (defined as having active suicidal ideation, intent or plan, or a serious suicide attempt within the past 6 months, or a baseline CDRS-R suicide score of \>3). * Hospitalized within the last 3 months * Greater than 1 year outside appropriate age/grade level * Pacemaker * Cerebral aneurysm clip * Cochlear implant * Metal fragments lodged within the eye or braces * Claustrophobia * Necessity of sedation (no sedation will be given). * History of loss of consciousness \> 10 minutes in duration * Allergy to seafood.